TN2009000530A1 - N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors - Google Patents

N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Info

Publication number: TN2009000530A1
Authority: TN; Tunisia
Prior art keywords: compound; treatment; piperidinedicarboxamide; ethoxyethyl; pyridinyl
Prior art date: 2007-06-25

Application number

TNP2009000530A

Other languages

English (en)

Inventor

Fumiaki Yokokawa

Takeru Ehara

Shimpei Kawakami

Osamu Irie

Masaki Suzuki

Yuko Hitomi

Atsushi Toyao

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-25

Filing date

2009-12-17

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-17 Application filed by Novartis Ag filed Critical Novartis Ag

2011-03-31 Publication of TN2009000530A1 publication Critical patent/TN2009000530A1/fr

Links

239000002461 renin inhibitor Substances 0.000 title 1
229940086526 renin-inhibitors Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
102100028255 Renin Human genes 0.000 abstract 3
108090000783 Renin Proteins 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2009000530A 2007-06-25 2009-12-17 N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors TN2009000530A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07012412		2007-06-25
EP07111290		2007-06-28
PCT/EP2008/057964 WO2009000811A1 (fr)	2007-06-25	2008-06-23	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2009000530A1 true TN2009000530A1 (en)	2011-03-31

Family

ID=39926743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000530A TN2009000530A1 (en)	2007-06-25	2009-12-17	N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Country Status (26)

Country	Link
US (2)	US8383650B2 (fr)
EP (2)	EP2181105B1 (fr)
JP (1)	JP5086433B2 (fr)
KR (1)	KR101238479B1 (fr)
CN (1)	CN101687847B (fr)
AR (1)	AR067132A1 (fr)
AU (1)	AU2008267287B2 (fr)
BR (1)	BRPI0813900A2 (fr)
CA (1)	CA2689109A1 (fr)
CL (1)	CL2008001872A1 (fr)
CO (1)	CO6251267A2 (fr)
CR (1)	CR11153A (fr)
CU (1)	CU23842B1 (fr)
EA (1)	EA016446B1 (fr)
EC (1)	ECSP099825A (fr)
ES (2)	ES2543641T3 (fr)
GT (1)	GT200900324A (fr)
HN (1)	HN2009003463A (fr)
IL (1)	IL202494A0 (fr)
MA (1)	MA31538B1 (fr)
NZ (1)	NZ582098A (fr)
PE (1)	PE20090425A1 (fr)
SG (1)	SG182223A1 (fr)
TN (1)	TN2009000530A1 (fr)
TW (1)	TWI404714B (fr)
WO (1)	WO2009000811A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0813900A2 (pt)	2007-06-25	2014-12-30	Novartis Ag	Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina
US20180048921A1 (en) *	2016-08-12	2018-02-15	Microsoft Technology Licensing, Llc	Real-time playback diagnostics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2090956T3 (es)	1991-12-18	1996-10-16	Schering Corp	Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.
IL111176A0 (en)	1993-10-07	1994-12-29	Du Pont Merck Pharma	Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
HUP9900926A3 (en)	1995-09-07	2002-12-28	Hoffmann La Roche	New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
EP0862435A4 (fr)	1995-11-22	1999-02-03	Merck & Co Inc	Inhibiteurs de la farnesyl-proteine transferase
WO1999009984A1 (fr)	1997-08-28	1999-03-04	Merck & Co., Inc.	Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine
WO1999065867A1 (fr)	1998-06-17	1999-12-23	Du Pont Pharmaceuticals Company	Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
US6274735B1 (en)	1998-08-10	2001-08-14	Hoffmann-La Roche Inc.	Process and intermediates for preparation of substituted piperidines
JP2002528543A (ja)	1998-10-30	2002-09-03	メルクエンドカムパニーインコーポレーテッド	トロンビン阻害剤
AU3386700A (en)	1999-03-02	2000-09-21	Merck & Co., Inc.	3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
AU3389300A (en)	1999-03-02	2000-09-21	Merck & Co., Inc.	Pyrrolidine modulators of chemokine receptor activity
US6362201B1 (en)	1999-03-02	2002-03-26	Merck & Co., Inc.	3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (fr)	1999-04-14	2000-10-26	F. Hoffmann-La Roche Ag	Procede de preparation de piperidines substituees
US6376672B1 (en)	1999-04-27	2002-04-23	Hoffmann-La Roche Inc.	Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en)	1999-04-27	2001-03-06	Hoffmann-La Roche Inc.	Piperidine derivatives
KR20030009391A (ko)	2000-03-17	2003-01-29	브리스톨-마이어스 스퀴브 파마 컴파니	기질 금속단백분해효소 및 ＴＮＦ-α의 억제제인 시클릭β-아미노산 유도체
FR2811673B1 (fr)	2000-07-17	2002-09-13	Rhodia Chimie Sa	Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
EP1326619A2 (fr)	2000-10-11	2003-07-16	Merck & Co., Inc.	Modulateurs a base de pyrrolidine d'activite de recepteur de chimiokines ccr5
US20060079533A1 (en)	2001-03-23	2006-04-13	Nieman James A	Methods of treating alzheimer's disease
US20030095958A1 (en)	2001-04-27	2003-05-22	Bhisetti Govinda R.	Inhibitors of bace
AU2002341715A1 (en)	2001-09-17	2003-04-01	Bristol-Myers Squibb Company	Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
WO2003031443A1 (fr)	2001-10-04	2003-04-17	Morphochem Aktiengesellschaft für kombinatorische Chemie	Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
CA2483241C (fr)	2002-04-29	2011-05-31	Actelion Pharmaceuticals Ltd	Nouveaux derives de diazabicyclononene
JP4271148B2 (ja)	2002-05-20	2009-06-03	ブリストル−マイヤーズスクイブカンパニー	置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
PL374860A1 (en)	2002-07-09	2005-11-14	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en)	2003-04-10	2004-10-14	Cody Wayne Livingston	Piperidine derivative rennin inhibitors
US20040214832A1 (en)	2003-04-10	2004-10-28	Cuiman Cai	Piperazine derivative renin inhibitors
US20060217371A1 (en)	2003-04-28	2006-09-28	Olivier Bezencon	Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
RU2005136986A (ru)	2003-04-29	2006-05-27	Актелион Фармасьютикалз Лтд. (Ch)	Новые 3,4-дизамещенные производные 1,2,3,6-тетрагидропиридина
BRPI0409878A (pt)	2003-04-30	2006-05-23	Actelion Pharmaceuticals Ltd	compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
KR20060008937A (ko)	2003-04-30	2006-01-27	액테리온 파마슈티칼 리미티드	레닌 억제제로서 3-위치에 헤테로원자를 갖는9-아자비사이클로[3.3.1]논-6-엔 유도체
KR20060006069A (ko)	2003-04-30	2006-01-18	액테리온 파마슈티칼 리미티드	아자비사이클로노넨 유도체
WO2004096116A2 (fr)	2003-05-02	2004-11-11	Actelion Pharmaceuticals Ltd	Derives de diazabicyclononene
US7144907B2 (en)	2003-09-03	2006-12-05	Array Biopharma Inc.	Heterocyclic inhibitors of MEK and methods of use thereof
TW200900399A (en)	2003-10-01	2009-01-01	Speedel Experimenta Ag	Organic compounds
CA2540543A1 (fr)	2003-10-09	2005-05-06	Actelion Pharmaceuticals Ltd	Derives de tetrahydropyridine
CA2600973C (fr)	2003-11-26	2012-08-07	Novartis Ag	Acide .delta.-amino-.gamma.-hydroxy-.omega.-arylalcanoique
PL1689712T3 (pl)	2003-11-26	2010-01-29	Novartis Ag	Pochodne 4-fenylopiperydyny jako inhibitory reniny
BRPI0506490A (pt)	2004-01-23	2007-02-13	Speedel Experimenta Ag	compostos orgánicos
ES2357585T3 (es)	2004-01-23	2011-04-27	Novartis Ag	Derivados de aminoalcoholes y su actividad como inhibidores de la renina.
BRPI0507067A (pt)	2004-01-23	2007-06-12	Speedel Experimenta Ag	diamino álcoois e seu uso como inibidores de renina
TW200536539A (en)	2004-03-19	2005-11-16	Speedel Experimenta Ag	Organic compounds
JP4927704B2 (ja)	2004-03-19	2012-05-09	シュペーデル・エクスペリメンタ・アーゲー	有機化合物
AR053406A1 (es)	2004-07-09	2007-05-09	Speedel Experimenta Ag	Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas
TW200631929A (en)	2004-12-10	2006-09-16	Speedel Experimenta Ag	ω -phenyloctanamides
GB0428250D0 (en)	2004-12-23	2005-01-26	Novartis Ag	Organic compounds
GB0428526D0 (en)	2004-12-30	2005-02-09	Novartis Ag	Organic compounds
GB0500784D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
GB0504850D0 (en)	2005-03-09	2005-04-13	Novartis Ag	Organic compounds
JP2008532983A (ja)	2005-03-11	2008-08-21	シュペーデル・エクスペリメンタ・アーゲー	レニン阻害剤として有用な複素環置換アルカンアミド
GB0505969D0 (en)	2005-03-23	2005-04-27	Novartis Ag	Organic compounds
TW200722424A (en)	2005-03-31	2007-06-16	Speedel Experimenta Ag	Substituted piperidines
US20090270380A1 (en)	2005-03-31	2009-10-29	Peter Herold	3,4,5-Substituted Piperidines as Renin Inhibitors
GB0508992D0 (en) *	2005-05-03	2005-06-08	Novartis Ag	Organic compounds
GB0510810D0 (en)	2005-05-26	2005-06-29	Novartis Ag	Organic compounds
GB0511063D0 (en)	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0514203D0 (en) *	2005-07-11	2005-08-17	Novartis Ag	Organic compounds
WO2007031558A1 (fr)	2005-09-17	2007-03-22	Speedel Experimenta Ag	Amides d'acide alcanoïque bicyclo- ou spiro-substitués
PL1937248T3 (pl)	2005-09-17	2010-11-30	Novartis Ag	Amidy kwasów alkanowych podstawione nasyconymi grupami O-heterocyklicznymi
PE20071079A1 (es) *	2005-11-15	2007-12-16	Cytokinetics Inc	Compuestos de piperidina como inhibidores de la proliferacion celular
JP5306821B2 (ja) *	2005-12-30	2013-10-02	ノバルティスアーゲー	レニン阻害剤としての３，５−置換ピペリジン化合物
EP1816122A3 (fr) *	2006-01-19	2007-09-19	Speedel Experimenta AG	Pipéridines substituées 3,4,5 en tant que composants thérapeutiques
EP1979323A1 (fr)	2006-01-30	2008-10-15	Speedel Experimenta AG	Procede de preparation de composes organiques
EP2044059A1 (fr)	2006-06-08	2009-04-08	Speedel Experimenta AG	Pipéridines 2,5-disubstituées
GB0611696D0 (en)	2006-06-13	2006-07-26	Novartis Ag	Organic compounds
GB0611697D0 (en)	2006-06-13	2006-07-26	Novartis Ag	Organic compounds
TW200831463A (en)	2006-09-12	2008-08-01	Speedel Experimenta Ag	Nitrate esters of aminoalcohols
EP1908471A1 (fr)	2006-10-04	2008-04-09	Speedel Experimenta AG	Tétrahydropyridines comme inhibiteurs de la renine
EP1921069A1 (fr)	2006-11-08	2008-05-14	Speedel Experimenta AG	Procédé de préparation de 2-alkyl-3-hétérocyclyl-prop-2-èn-1-ols
AR065792A1 (es)	2007-03-21	2009-07-01	Speedel Experimenta Ag	Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona
BRPI0813900A2 (pt)	2007-06-25	2014-12-30	Novartis Ag	Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina

2008
- 2008-06-23 BR BRPI0813900-8A2A patent/BRPI0813900A2/pt not_active IP Right Cessation
- 2008-06-23 JP JP2010513876A patent/JP5086433B2/ja not_active Expired - Fee Related
- 2008-06-23 EA EA201000037A patent/EA016446B1/ru not_active IP Right Cessation
- 2008-06-23 NZ NZ582098A patent/NZ582098A/en not_active IP Right Cessation
- 2008-06-23 AR ARP080102691A patent/AR067132A1/es not_active Application Discontinuation
- 2008-06-23 CA CA002689109A patent/CA2689109A1/fr not_active Abandoned
- 2008-06-23 KR KR1020097027047A patent/KR101238479B1/ko active Active
- 2008-06-23 EP EP08761309.7A patent/EP2181105B1/fr active Active
- 2008-06-23 SG SG2012046132A patent/SG182223A1/en unknown
- 2008-06-23 WO PCT/EP2008/057964 patent/WO2009000811A1/fr active Application Filing
- 2008-06-23 AU AU2008267287A patent/AU2008267287B2/en not_active Ceased
- 2008-06-23 EP EP20120176689 patent/EP2527338B1/fr active Active
- 2008-06-23 ES ES12176689.3T patent/ES2543641T3/es active Active
- 2008-06-23 CN CN2008800218979A patent/CN101687847B/zh not_active Expired - Fee Related
- 2008-06-23 ES ES08761309.7T patent/ES2541107T3/es active Active
- 2008-06-24 TW TW097123556A patent/TWI404714B/zh not_active IP Right Cessation
- 2008-06-24 PE PE2008001078A patent/PE20090425A1/es not_active Application Discontinuation
- 2008-06-24 CL CL2008001872A patent/CL2008001872A1/es unknown
- 2008-06-25 US US12/146,073 patent/US8383650B2/en not_active Expired - Fee Related
2009
- 2009-12-03 IL IL202494A patent/IL202494A0/en unknown
- 2009-12-09 CR CR11153A patent/CR11153A/es unknown
- 2009-12-17 TN TNP2009000530A patent/TN2009000530A1/fr unknown
- 2009-12-18 GT GT200900324A patent/GT200900324A/es unknown
- 2009-12-22 HN HN2009003463A patent/HN2009003463A/es unknown
- 2009-12-22 CO CO09146659A patent/CO6251267A2/es active IP Right Grant
- 2009-12-22 CU CU2009000226A patent/CU23842B1/es not_active IP Right Cessation
- 2009-12-23 EC EC2009009825A patent/ECSP099825A/es unknown
2010
- 2010-01-22 MA MA32543A patent/MA31538B1/fr unknown
2012
- 2012-09-14 US US13/616,081 patent/US8497286B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2008267287A1 (en)	2008-12-31
BRPI0813900A2 (pt)	2014-12-30
CN101687847A (zh)	2010-03-31
TWI404714B (zh)	2013-08-11
JP2010531328A (ja)	2010-09-24
CL2008001872A1 (es)	2009-02-20
PE20090425A1 (es)	2009-05-12
KR101238479B1 (ko)	2013-03-04
EP2527338A1 (fr)	2012-11-28
US20080319018A1 (en)	2008-12-25
CN101687847B (zh)	2013-11-06
CA2689109A1 (fr)	2008-12-31
AR067132A1 (es)	2009-09-30
CU23842B1 (es)	2012-10-15
MA31538B1 (fr)	2010-07-01
HN2009003463A (es)	2012-12-10
WO2009000811A1 (fr)	2008-12-31
US20130005770A1 (en)	2013-01-03
EA016446B1 (ru)	2012-05-30
JP5086433B2 (ja)	2012-11-28
CR11153A (es)	2010-01-21
SG182223A1 (en)	2012-07-30
EP2527338B1 (fr)	2015-05-06
ES2541107T3 (es)	2015-07-16
IL202494A0 (en)	2010-06-30
GT200900324A (es)	2011-11-03
EP2181105B1 (fr)	2015-04-29
CU20090226A7 (es)	2012-02-15
TW200911782A (en)	2009-03-16
EP2181105A1 (fr)	2010-05-05
ES2543641T3 (es)	2015-08-20
US8383650B2 (en)	2013-02-26
EA201000037A1 (ru)	2010-06-30
KR20100023003A (ko)	2010-03-03
CO6251267A2 (es)	2011-02-21
AU2008267287B2 (en)	2012-02-16
ECSP099825A (es)	2010-01-29
NZ582098A (en)	2012-03-30
US8497286B2 (en)	2013-07-30

Publication	Publication Date	Title
TW200738698A (en)	2007-10-16	Organic compounds
MX2007011009A (es)	2007-09-26	Compuestos de piperidina 3,4,5-substituidos.
GEP20125425B (en)	2012-03-26	Biaryl ether urea compounds
MX2009006401A (es)	2009-06-23	Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
TNSN06411A1 (en)	2008-02-22	Pyrimidine urea derivatives as kinase inhibitors
BRPI0813244B8 (pt)	2021-05-25	compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
MX2009010059A (es)	2009-10-12	Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
PH12013501594A1 (en)	2014-05-12	Substituted indazole derivatives active as kinase inhibitors
TW200833663A (en)	2008-08-16	Therapeutic agents
MY155649A (en)	2015-11-13	Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2005075425A3 (fr)	2006-12-14	Derives de bisaryluree
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
WO2006072589A3 (fr)	2006-10-12	Urees disubstituees utilisees en tant qu'inhibiteurs de kinase
WO2006085113A3 (fr)	2006-10-26	Composes chimiques
WO2011127333A3 (fr)	2012-02-02	Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
EP2349279A4 (fr)	2013-12-25	Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
MX2008013212A (es)	2008-10-22	4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2007006534A3 (fr)	2007-04-19	Composes organiques
WO2006125621A8 (fr)	2008-03-27	Piperidines substituees utilisees comme inhibiteurs de la renine
MX2012003324A (es)	2012-04-30	Compuesto de glicina.
WO2006074924A8 (fr)	2007-04-19	Tetrahydropyridines 3,4(,5) substituees
WO2011006935A3 (fr)	2013-03-28	Dérivés de tétrazole
GB0428250D0 (en)	2005-01-26	Organic compounds
MA32406B1 (fr)	2011-06-01	Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
WO2010121675A3 (fr)	2011-02-24	Thiazolyl-benzimidazoles